Manufacturing

Growth in Cell and Gene Therapy Market

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Continuous Processing for Viral Vectors

Manufacturers are taking the first steps toward process intensification.

Overcoming Engineering Challenges to Enable Commercial Scale mRNA Vaccine Manufacturing

This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.

Boehringer Ingelheim Adopts Virtuosi VR Education Platform

September 21, 2022

Boehringer Ingelheim will use Virtuosi to train employees at three aseptic sites across its network.

Civica to Invest $27.8 Million in New Testing Facility

September 19, 2022

Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.

Advanced Biopharma Manufacturing Key to White House Cancer Moonshot

September 16, 2022

The White House hopes to expand US modern biotech manufacturing and reduce reliance on foreign sources of bioindustrial materials.

Accelerating the Development of mRNA Therapeutics

September 16, 2022

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Real-Time Post-Apheresis Documentation Decreases Errors

September 15, 2022

Document integrity is critical in the provision of raw materials for cell and gene therapy manufacturing.

The Road to Personalized Medicine: Reimagining Drug Manufacturing

September 15, 2022

For cell and gene therapies to reach their full potential, changes in manufacturing must be explored.

MilliporeSigma to Invest €130 Million in French Manufacturing Facility

September 14, 2022

MilliporeSigma’s €130 million (USD$132 million) investment is designed to increase manufacturing capacity of single-use assemblies.

Charles River and Cure AP-4 Announce Manufacturing Collaboration

September 09, 2022

Charles River Laboratories and Cure AP-4 will collaborate on gene therapy manufacturing for AP-4 hereditary spastic paraplegia.

Hovione Expands its Continuous Manufacturing Offering and Services

September 06, 2022

Hovione has expanded its drug product offering with a new manufacturing line dedicated to continuous tableting.

Streamlining Bulk mAb Manufacturing

September 02, 2022

The projected growth in the biosimilars market will require increased bulk mAb manufacturing.